These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7705096)

  • 1. Dose-finding study of a contraceptive ring releasing norethindrone acetate/ethinyl estradiol.
    Ballagh SA; Mishell DR; Jackanicz TM; Lacarra M; Eggena P
    Contraception; 1994 Dec; 50(6):535-49. PubMed ID: 7705096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol.
    Ballagh SA; Mishell DR; Lacarra M; Shoupe D; Jackanicz TM; Eggena P
    Contraception; 1994 Dec; 50(6):517-33. PubMed ID: 7705095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
    Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
    Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Nash HA
    Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Jackanicz T
    Contraception; 1997 Oct; 56(4):233-9. PubMed ID: 9408704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
    Victor A; Lithell H; Selinus I; Vessby B
    Ups J Med Sci; 1984; 89(2):179-88. PubMed ID: 6380076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
    Moutos D; Smith S; Zacur H
    Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
    Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
    Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels.
    Saleh WA; Burkman RT; Zacur HA; Kimball AW; Kwiterovich P; Bell WK
    Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 1):1740-5; discussion 1745-7. PubMed ID: 8317516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol.
    Goebelsmann U; Mashchak CA; Mishell DR
    Am J Obstet Gynecol; 1985 Apr; 151(7):868-77. PubMed ID: 3920910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matched-pairs analysis of ovarian suppression during oral vs. vaginal hormonal contraceptive use.
    Petrie KA; Torgal AH; Westhoff CL
    Contraception; 2011 Nov; 84(5):e1-4. PubMed ID: 22018131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contraception in older woman.
    Volpe A; Silferi M; Genazzani AD; Genazzani AR
    Contraception; 1993 Mar; 47(3):229-39. PubMed ID: 8462314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
    Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B
    Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol.
    Boyd RA; Zegarac EA; Posvar EL; Flack MR
    Contraception; 2001 Feb; 63(2):71-6. PubMed ID: 11292470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and biological justifications for the use of Triella].
    McGuire JL; Pasquale SA; Castaigne JP
    Rev Fr Gynecol Obstet; 1986 Dec; 81(12):731-6. PubMed ID: 3823727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestogen-only microdose followed by estrogen-progestogen combination, a new approach to oral contraception.
    Russowsky M; Sartoretto JN
    Contraception; 1982 Jul; 26(1):41-9. PubMed ID: 7128133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
    Wild RA; Demers LM; Applebaum-Bowden D; Lenker R
    Contraception; 1991 Aug; 44(2):113-24. PubMed ID: 1893706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.